These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 9212731)
21. Corticomedullary differentiation and maturational arrest in thymomas. Ströbel P; Hartmann E; Rosenwald A; Kalla J; Ott G; Friedel G; Schalke B; Kasahara M; Tomaru U; Marx A Histopathology; 2014 Mar; 64(4):557-66. PubMed ID: 24236644 [TBL] [Abstract][Full Text] [Related]
22. L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M J Surg Oncol; 2009 Jun; 99(7):433-8. PubMed ID: 19347882 [TBL] [Abstract][Full Text] [Related]
23. Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of myasthenia gravis. Marx A; Wilisch A; Schultz A; Greiner A; Magi B; Pallini V; Schalke B; Toyka K; Nix W; Kirchner T; Müller-Hermelink HK Am J Pathol; 1996 Jun; 148(6):1839-50. PubMed ID: 8669470 [TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor expression in invasive thymoma. Henley JD; Koukoulis GK; Loehrer PJ J Cancer Res Clin Oncol; 2002 Mar; 128(3):167-70. PubMed ID: 11935304 [TBL] [Abstract][Full Text] [Related]
25. [Thymoma with epithelial micronodules and lymphoid hyperplasia: six cases of a rare and equivocal subtype]. Thomas De Montpréville V; Zemoura L; Dulmet E Ann Pathol; 2002 Jun; 22(3):177-82. PubMed ID: 12410100 [TBL] [Abstract][Full Text] [Related]
26. Estrogen inhibits cell proliferation through in situ production in human thymoma. Ishibashi H; Suzuki T; Suzuki S; Moriya T; Kaneko C; Nakata T; Sunamori M; Handa M; Kondo T; Sasano H Clin Cancer Res; 2005 Sep; 11(18):6495-504. PubMed ID: 16166425 [TBL] [Abstract][Full Text] [Related]
27. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188 [TBL] [Abstract][Full Text] [Related]
28. PE-35-related antigen expression and CD1a-positive lymphocytes in thymoma subtypes based on Müller-Hermelink classification. An immunohistochemical study using catalyzed signal amplification. Hattori H; Tateyama H; Tada T; Saito Y; Yamakawa Y; Eimoto T Virchows Arch; 2000 Jan; 436(1):20-7. PubMed ID: 10664158 [TBL] [Abstract][Full Text] [Related]
29. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868 [TBL] [Abstract][Full Text] [Related]
30. Corpuscular thymoma: entity or variant of organotypical thymomas WHO B2/B3? Laeng RH; Eimoto T; Kuo TT; Zettl A; Marx A; Moschopulos M; Tateyama H; Shimokawa K Pathol Res Pract; 2006; 202(10):697-704. PubMed ID: 16887284 [TBL] [Abstract][Full Text] [Related]
31. Thymoma: an integrated clinicopathological and immunohistochemical study. Ring NP; Addis BJ J Pathol; 1986 Aug; 149(4):327-37. PubMed ID: 2428964 [TBL] [Abstract][Full Text] [Related]
32. Tissue distribution of very late activation antigens-1/6 and very late activation antigen ligands in the normal thymus and in thymoma. Ruco LP; Paradiso P; Pittiglio M; Diodoro MG; Gearing AJ; Mainiero F; Gismondi A; Santoni A; Baroni CD Am J Pathol; 1993 Mar; 142(3):765-72. PubMed ID: 8456937 [TBL] [Abstract][Full Text] [Related]
33. Expression of E-cadherin and alpha- and beta-catenins in thymoma. Pan CC; Ho DM; Chen WY; Chiang H; Fahn HJ; Wang LS J Pathol; 1998 Feb; 184(2):207-11. PubMed ID: 9602713 [TBL] [Abstract][Full Text] [Related]
34. [Correlation between clinical aggressiveness of thymic epithelial tumors and expression of tumor suppressor gene products (p53, p27)]. Fukiwake N; Kase S; Yamazaki K; Yano T; Sugimachi K Fukuoka Igaku Zasshi; 1999 Aug; 90(8):339-41. PubMed ID: 10496046 [TBL] [Abstract][Full Text] [Related]
35. CD5 expression in thymic carcinoma. Hishima T; Fukayama M; Fujisawa M; Hayashi Y; Arai K; Funata N; Koike M Am J Pathol; 1994 Aug; 145(2):268-75. PubMed ID: 7519823 [TBL] [Abstract][Full Text] [Related]
36. Comparative morphologic and immunohistochemical investigation of spontaneously occurring thymomas in a colony of European hamsters. Brandes K; Fend F; Monecke S; Teifke JP; Breuer W; Hermanns W Vet Pathol; 2004 Jul; 41(4):346-52. PubMed ID: 15232134 [TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277 [TBL] [Abstract][Full Text] [Related]
38. Absence of gene mutations in KIT-positive thymic epithelial tumors. Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988 [TBL] [Abstract][Full Text] [Related]
39. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors. Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061 [TBL] [Abstract][Full Text] [Related]